ZyVersa Therapeutics Statistics
Total Valuation
ZVSA has a market cap or net worth of $3.26 million. The enterprise value is $1.23 million.
| Market Cap | 3.26M |
| Enterprise Value | 1.23M |
Important Dates
The next estimated earnings date is Monday, August 19, 2024, after market close.
| Earnings Date | Aug 19, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ZVSA has 834,896 shares outstanding. The number of shares has increased by 2,291.01% in one year.
| Shares Outstanding | 834,896 |
| Shares Change (YoY) | +2,291.01% |
| Shares Change (QoQ) | +539.56% |
| Owned by Insiders (%) | 0.75% |
| Owned by Institutions (%) | 1.37% |
| Float | 825,420 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.29 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.30, with zero debt.
| Current Ratio | 0.30 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -146,595.84 |
Financial Efficiency
Return on equity (ROE) is -680.10% and return on invested capital (ROIC) is -944.38%.
| Return on Equity (ROE) | -680.10% |
| Return on Assets (ROA) | -388.70% |
| Return on Capital (ROIC) | -944.38% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$15.08M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -8.41M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -94.88% in the last 52 weeks. The beta is 0.65, so ZVSA's price volatility has been lower than the market average.
| Beta (5Y) | 0.65 |
| 52-Week Price Change | -94.88% |
| 50-Day Moving Average | 4.51 |
| 200-Day Moving Average | 12.91 |
| Relative Strength Index (RSI) | 44.25 |
| Average Volume (20 Days) | 270,454 |
Short Selling Information
The latest short interest is 18,894, so 2.26% of the outstanding shares have been sold short.
| Short Interest | 18,894 |
| Short Previous Month | 34,976 |
| Short % of Shares Out | 2.26% |
| Short % of Float | 2.29% |
| Short Ratio (days to cover) | 0.25 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -105.99M |
| Pretax Income | -105.99M |
| Net Income | -105.53M |
| EBITDA | -105.98M |
| EBIT | -105.99M |
| Earnings Per Share (EPS) | -$1,145.53 |
Balance Sheet
The company has $2.03 million in cash and no debt, giving a net cash position of $2.03 million or $2.44 per share.
| Cash & Cash Equivalents | 2.03M |
| Total Debt | n/a |
| Net Cash | 2.03M |
| Net Cash Per Share | $2.44 |
| Equity (Book Value) | 11.22M |
| Book Value Per Share | 13.44 |
| Working Capital | -6.68M |
Cash Flow
| Operating Cash Flow | -7.91M |
| Capital Expenditures | n/a |
| Free Cash Flow | -7.91M |
| FCF Per Share | -$12.68 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ZVSA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2,291.01% |
| Shareholder Yield | -2,291.01% |
| Earnings Yield | -3,232.68% |
| FCF Yield | -242.25% |
Analyst Forecast
The average price target for ZVSA is $240.00, which is 6,038.11% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $240.00 |
| Price Target Difference | 6,038.11% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -44.38% |
Stock Splits
The last stock split was on April 26, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Apr 26, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |